• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

KalVista - Articles and news items


KalVista initiates KVD818 trial to find treatment for hereditary angioedema

Industry news / 11 August 2016 / KalVista

This first clinical study will evaluate the key characteristics of safety, drug exposure and bioactivity (plasma kallikrein inhibition) achieved after oral dosing of KVD818. This clinical trial is being conducted in the UK with results of the study expected in spring 2017…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +